Literature DB >> 27424155

Protein complex formation and intranuclear dynamics of NAC1 in cancer cells.

Naomi Nakayama1, Hiroaki Kato1, Gyosuke Sakashita1, Yuko Nariai1, Kentaro Nakayama2, Satoru Kyo2, Takeshi Urano3.   

Abstract

Nucleus accumbens-associated protein 1 (NAC1) is a cancer-related transcription regulator protein that is also involved in the pluripotency and differentiation of embryonic stem cells. NAC1 is overexpressed in various carcinomas including ovarian, cervical, breast, and pancreatic carcinomas. NAC1 knock-down was previously shown to result in the apoptosis of ovarian cancer cell lines and to rescue their sensitivity to chemotherapy, suggesting that NAC1 may be a potential therapeutic target, but protein complex formation and the dynamics of intranuclear NAC1 in cancer cells remain poorly understood. In this study, analysis of HeLa cell lysates by fast protein liquid chromatography (FPLC) on a sizing column showed that the NAC1 peak corresponded to an apparent molecular mass of 300-500 kDa, which is larger than the estimated molecular mass (58 kDa) of the protein. Furthermore, live cell photobleaching analyses with green fluorescent protein (GFP)-fused NAC1 proteins revealed the intranuclear dynamics of NAC1. Collectively our results demonstrate that NAC1 forms a protein complex to function as a transcriptional regulator in cancer cells.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Fluorescence loss in photobleaching (FLIP); Fluorescence recovery after photobleaching (FRAP); Intranuclear dynamics; Live cell photobleaching analysis; Nucleus accumbens-associated protein 1 (NAC1); Protein complex formation

Mesh:

Substances:

Year:  2016        PMID: 27424155     DOI: 10.1016/j.abb.2016.07.007

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  7 in total

1.  miR-18a-5p derived from mesenchymal stem cells-extracellular vesicles inhibits ovarian cancer cell proliferation, migration, invasion, and chemotherapy resistance.

Authors:  Xiaoying Wang; Lili Jiang; Qifang Liu
Journal:  J Transl Med       Date:  2022-06-07       Impact factor: 8.440

2.  Unclassified low grade spindle cell sarcoma with storiform pattern characterized by recurrent novel EWSR1/FUS-NACC1 fusions.

Authors:  Cristina R Antonescu; Brendan C Dickson; Lei Zhang; Yun-Shao Sung; Christopher D Fletcher
Journal:  Mod Pathol       Date:  2021-04-15       Impact factor: 7.842

3.  MiR-361-3p alleviates cerebral ischemia-reperfusion injury by targeting NACC1 through the PINK1/Parkin pathway.

Authors:  Xihong Ye; Hua Song; Huimin Hu; Chunli Zhou; Qinyi Chen; Lin Hong; Min Huang; Hongfei Zhu
Journal:  J Mol Histol       Date:  2022-01-24       Impact factor: 2.611

4.  G196 epitope tag system: a novel monoclonal antibody, G196, recognizes the small, soluble peptide DLVPR with high affinity.

Authors:  Kasumi Tatsumi; Gyosuke Sakashita; Yuko Nariai; Kosuke Okazaki; Hiroaki Kato; Eiji Obayashi; Hisashi Yoshida; Kanako Sugiyama; Sam-Yong Park; Joji Sekine; Takeshi Urano
Journal:  Sci Rep       Date:  2017-03-07       Impact factor: 4.379

5.  Cancer-related transcription regulator protein NAC1 forms a protein complex with CARM1 for ovarian cancer progression.

Authors:  Naomi Nakayama; Gyosuke Sakashita; Yuko Nariai; Hiroaki Kato; Kaori Sinmyozu; Jun-Ichi Nakayama; Satoru Kyo; Takeshi Urano; Kentaro Nakayama
Journal:  Oncotarget       Date:  2018-06-19

6.  Silencing of NAC1 Expression Induces Cancer Cells Oxidative Stress in Hypoxia and Potentiates the Therapeutic Activity of Elesclomol.

Authors:  Yi-Jie Ren; Xiao-Hui Wang; Cheng Ji; Yi-Di Guan; Xian-Jiu Lu; Xian-Rong Liu; Hong-Han Zhang; Ling-Chuan Guo; Qiong-Hua Xu; Wei-Dong Zhu; Zhi-Jun Ming; Jin-Ming Yang; Yan Cheng; Yi Zhang
Journal:  Front Pharmacol       Date:  2017-11-07       Impact factor: 5.810

7.  NACC1, as a Target of MicroRNA-331-3p, Regulates Cell Proliferation in Urothelial Carcinoma Cells.

Authors:  Kohei Morita; Tomomi Fujii; Hiroe Itami; Tomoko Uchiyama; Tokiko Nakai; Kinta Hatakeyama; Aya Sugimoto; Makito Miyake; Yasushi Nakai; Nobumichi Tanaka; Keiji Shimada; Masaharu Yamazaki; Kiyohide Fujimoto; Chiho Ohbayashi
Journal:  Cancers (Basel)       Date:  2018-09-21       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.